Zentalis Pharmaceuticals Inc. (ZNTL)
$3.99
$-0.12
(-2.92%)
As on 04-Sep-2026 18:23EDT
Market cap
$378 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.5
-
Face value
--
-
Shares outstanding
94,671,914
6 Years Aggregate
CFO
$-675.89 Mln
EBITDA
$-944.29 Mln
Net Profit
$-863.28 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
| 195.6 | -14.2 | 7.3 | 133.3 | -47.2 | -43.0 | -- |
|
BSE Sensex*
| -10.1 | -3.6 | 2.5 | -5.7 | 4.9 | 5.5 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
| -55.4 | -79.7 | -24.8 | -76.0 | 61.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
4.0 | 377.7 | 0.0 | -174.9 | -- | -97.2 | -- | 2.4 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3... clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California. Read more
-
CEO & Director
Dr. Kimberly Lynn Blackwell M.D.
-
CEO & Director
Dr. Kimberly Lynn Blackwell M.D.
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Zentalis Pharmaceuticals (ZNTL)
What is the current share price of Zentalis Pharmaceuticals Inc (ZNTL) Today?
The share price of Zentalis Pharmaceuticals Inc (ZNTL) is $3.99 (NASDAQ) as of 04-Sep-2026 18:23 EDT. Zentalis Pharmaceuticals Inc (ZNTL) has given a return of -47.22% in the last 3 years.
What is the current PB & PE ratio of Zentalis Pharmaceuticals Inc (ZNTL)?
Since, TTM earnings of Zentalis Pharmaceuticals Inc (ZNTL) is negative, P/E ratio is not available.
The P/B ratio of Zentalis Pharmaceuticals Inc (ZNTL) is 2.45 times as on 04-Sep-2026, a 54 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.71 |
0.45 |
2024 |
-1.30 |
0.64 |
2023 |
-3.67 |
2.45 |
2022 |
-5.04 |
2.75 |
2021 |
-23.82 |
10.39 |
What is the 52 Week High and Low of Zentalis Pharmaceuticals Inc (ZNTL)?
The 52-week high and low of Zentalis Pharmaceuticals Inc (ZNTL) are Rs 6.95 and Rs 1.21 as of 08-Sep-2026.
What is the market cap of Zentalis Pharmaceuticals Inc (ZNTL)?
Zentalis Pharmaceuticals Inc (ZNTL) has a market capitalisation of $ 378 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Zentalis Pharmaceuticals Inc (ZNTL)?
Before investing in Zentalis Pharmaceuticals Inc (ZNTL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.